Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer
By: prepared for Agency for Health Care Policy and Research ; prepared by Blue Cross and Blue Shield Association ; Naomi Aronson, program director ... [et al.].
Contributors: Aronson, Naomi.; United States. Agency for Health Care Policy and Research.; Blue Cross and Blue Shield Association.
Series: AHCPR publication -- no. 99-E0012; Evidence report/technology assessment -- no. 4.; AHCPR pub -- no. 99-E012.
Publisher: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research
Published: 1999
Place of publication: Rockville, Md
Language: eng
Subjects: Prostatic Neoplasms -- drug therapy; Antineoplastic Agents, Hormonal -- therapeutic use; Cost-Benefit Analysis; Gonadotropin-Releasing Hormone -- agonists; Treatment Outcome; Evidence-Based Medicine -- methods
Notes: in: Evidence report/technology assessment ; no. 4.

"Contract no. 290-97-0015."

"May 1999."

Includes bibliographical references.